Physician profile
Don Alfonso
NPI 1073508917
$6,172.49
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,672 · 2020: $2,226 · 2021: $1,786 · 2022: $435 · 2023: $21.10 · 2024: $32.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $53.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $53.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,018.54 | 2019-2022 | |
| Novo Nordisk INC | $758.80 | 2019-2022 | |
| Amgen INC. | $555.55 | 2019-2022 | |
| Astellas Pharma US INC | $539.07 | 2019-2022 | |
| Abbvie INC. | $538.83 | 2019-2024 | Ubrelvy |
| Pfizer INC. | $470.10 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $361.62 | 2019-2021 | |
| Lilly USA, LLC | $307.65 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $239.38 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $232.61 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $136.59 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $132.48 | 2019-2022 | |
| Daiichi Sankyo INC. | $117.38 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $98.41 | 2020-2022 | |
| Arbor Pharmaceuticals, INC. | $91.23 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $83.26 | 2019-2020 | |
| Abbott Laboratories | $68.60 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $63.65 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $52.20 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.30 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $35.22 | 2021 | |
| Eisai INC. | $33.70 | 2020 | |
| Ibsa Pharma INC. | $33.14 | 2021 | |
| Ethicon US, LLC | $26.21 | 2019-2021 | |
| Horizon Therapeutics Plc | $25.08 | 2021 | |
| Xeris Pharmaceuticals, INC. | $23.25 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $18.82 | 2021 | |
| Circassia INC. | $15.92 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $15.00 | 2019 | |
| Almatica Pharma LLC | $13.93 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.81 | 2019 | |
| Axonics, INC. | $11.16 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Don Alfonso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.